

SPARC/Sec/SE/2025-26/09

June 3, 2025

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/ Madam,

Sub: SPARC provides update on Vibozilimod (SCD-044)

Pursuant to the requirement under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD). SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75% improvement in PASI (Psoriasis Area and Severity Index) score (\geq PASI75) at Week 16 and 75% improvement in EASI (Eczema Area and Severity Index) score (\geq EASI75) at Week 16 respectively.

SPARC and SPIL will evaluate the appropriate next steps for SCD-044.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For **Sun Pharma Advanced Research Company Ltd.**

Kajal Damania
Company Secretary and Compliance Officer